93 results
S-3ASR
EX-4.3
SANA
Sana Biotechnology Inc
1 Mar 24
Automatic shelf registration
4:08pm
read such covenant or condition;
-37-
(b) a brief statement as to the nature and scope of the examination or investigation upon which the statements
S-3ASR
SANA
Sana Biotechnology Inc
1 Mar 24
Automatic shelf registration
4:08pm
, and the nature and amount of each of those securities, or the method of determining those amounts;
whether the purchase contracts are to be prepaid
8-K
EX-99.1
SANA
Sana Biotechnology Inc
29 Feb 24
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
4:12pm
using an anti-CD47 antibody, demonstrating proof of principle of CD47 overexpression and a potential safety switch.
Published preclinical data in Nature … Communications, Science Translational Medicine, and Nature Biotechnology describing immune evasion, persistence, and durable anti-tumor activity
8-K
EX-1.1
SANA
Sana Biotechnology Inc
8 Feb 24
Sana Biotechnology Announces Pricing of Upsized Public Offering
5:20pm
ownership of Common Stock is required, it shall indicate in the footnotes thereto the nature and conditions of such transfer;
(h) transfers or dispositions
424B5
n65fk5c88wuun
8 Feb 24
Prospectus supplement for primary offering
4:49pm
424B5
wyze9 om92pvk5v
7 Feb 24
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
rcpth23a
9 Jan 24
Regulation FD Disclosure
9:00am
8-K
EX-99.1
9fo6aytzdgj3nq
11 Dec 23
Regulation FD Disclosure
4:01pm
8-K
EX-99.2
wouctqrq tnx3tjk88u
10 Oct 23
Cost Associated with Exit or Disposal Activities
4:21pm
8-K
EX-99.1
zwhffggtw
13 Sep 23
Regulation FD Disclosure
6:04am
8-K
EX-99.1
cy6 oaj7rm15y
3 Aug 23
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
4:14pm
8-K
EX-99.1
5hc6qb5 n7
7 Jun 23
Regulation FD Disclosure
6:00am
8-K
EX-99.1
vbtq4hciryw0d
8 May 23
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
4:25pm